Please ensure Javascript is enabled for purposes of website accessibility

Why Altimmune Shares Are Flying High Today

By Keith Speights – Jul 13, 2020 at 12:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are cheering the biotech's good news from its preclinical testing of an intranasal COVID-19 vaccine candidate.

What happened

Shares of Altimmune (ALT 1.32%) were flying 16.7% higher as of 11:27 a.m. EDT on Monday. The big jump came after the company and the University of Alabama at Birmingham (UAB) reported positive preclinical results for intranasal COVID-19 vaccine candidate AdCOVID.

So what

Altimmune and UAB reported that mice receiving AdCOVID demonstrated a "strong systemic antibody response" 14 days after receiving a single intranasal dose of the vaccine candidate. Lead investigator and UAB professor Dr. Frances Lund said, "Stimulation of immunity at this level just 14 days after a single dose is impressive for any vaccine, and is particularly notable for a potential coronavirus vaccine."

A scientist holds a mouse in her gloved hands.

Image source: Getty Images.

It's important to keep in mind, though, that success in preclinical testing doesn't always carry over into clinical studies. Human responses to vaccine candidates can be much different than the responses in mice.

Still, the preclinical results were great news for Altimmune. The biotech doesn't have any approved products on the market. Its lead pipeline candidate, intranasal flu vaccine NasoVAX, is ready for phase 2b testing. However, Altimmune is seeking a partner to advance the clinical development of the vaccine candidate.

Now what

Another major catalyst for the biotech stock could be on the way relatively soon. Altimmune plans to begin a phase 1 study of AdCOVID in the fourth quarter of 2020.  

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Altimmune, Inc. Stock Quote
Altimmune, Inc.
ALT
$13.00 (1.32%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.